Literature DB >> 2024372

Colocystoplasty for the treatment of severe interstitial cystitis.

M J Kontturi1, P A Hellström, T L Tammela, O A Lukkarinen.   

Abstract

Twelve patients with end-stage interstitial cystitis and intractable symptoms resistant to conservative measures underwent supratrigonal cystectomy and colocystoplasty, comprising 7 right colocystoplasties and 5 open-loop sigmoidocystoplasties. Mean follow-up was 4.7 years. Ten patients had complete relief of pain and a decrease in frequency, while 2 patients required cystectomy and urinary diversion because of persistent symptoms or infection and incontinence. Bladder function was evaluated urodynamically in 11 patients. The bladder capacities in the right colocystoplasties were between 325 and 800 ml (mean 495), compared with 180 and 500 ml (mean 345) in the sigmoideocystoplasties. Two patients suffered from mild urge incontinence. All the patients retained their sensation of bladder fullness and voided without difficulty. In only 3 cases was a procedure needed to lower the bladder outflow tract resistance. Most patients did not need long-term antibiotics. No impairment in renal function was noted. In view of the good results achieved colocystoplasty can be recommended more often for the treatment of interstitial cystitis, detubularized right colocystoplasty being the operation of choice.

Entities:  

Mesh:

Year:  1991        PMID: 2024372     DOI: 10.1159/000281774

Source DB:  PubMed          Journal:  Urol Int        ISSN: 0042-1138            Impact factor:   2.089


  2 in total

Review 1.  Global concepts of bladder pain syndrome (interstitial cystitis).

Authors:  Jørgen Nordling; Magnus Fall; Philip Hanno
Journal:  World J Urol       Date:  2011-11-05       Impact factor: 4.226

2.  Supratrigonal cystectomy and augmentation cystoplasty with ileum or ileocecum in the treatment of ulcerative interstitial cystitis/bladder pain syndrome: a 14-year follow-up.

Authors:  Fabian Queissert; Benedict Bruecher; Arndt van Ophoven; Andres J Schrader
Journal:  Int Urogynecol J       Date:  2022-03-01       Impact factor: 1.932

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.